Literature DB >> 18402814

Development of atherosclerosis in Balb/c apolipoprotein E-deficient mice.

Anjali Desai1, Ying Zhao, Jeffrey S Warren.   

Abstract

BACKGROUND: Since its creation in 1992 by gene inactivation via gene targeting, the apolipoprotein E "knockout" mouse has become the most widely used rodent model for the study of atherosclerosis. Commercially available apolipoprotein E(-/-) mice are bred on a C57BL/6J background. The goal of the present study was to investigate the development of atherosclerosis in apolipoprotein E-deficient mice generated on a Balb/c background.
METHODS: We compared serum cholesterol concentrations and the development of atherosclerotic lesions in heterozygous Balb/c [apolipoprotein E(+/-)] mice fed regular rodent chow, Balb/c apolipoprotein E-deficient mice fed regular chow, and Balb/c apolipoprotein E-deficient mice fed a high-fat diet for up to 30 weeks. Expression of the chemokine JE (murine homologue of MCP-1), as well as the adhesion molecules E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1, in the aortas of knockout mice fed a high-fat diet was measured by enzyme-linked immunosorbent assay.
RESULTS: Balb/c apolipoprotein E-deficient mice develop atherosclerotic lesions in a reproducible temporal and morphological pattern. Total serum cholesterol concentrations in Balb/c apolipoprotein E-deficient mice fed regular chow or a high-fat diet, respectively, closely parallel those reported for C57BL/6J apolipoprotein E-deficient mice. The expression of all three adhesion molecules in the aorta follows a similar temporal pattern, peaking in the first 15 weeks, whereas JE concentrations peak around 23 weeks.
CONCLUSION: The availability of Balb/c apolipoprotein E-deficient mice will facilitate the study of atherosclerosis in a mouse strain that can concomitantly develop other pathological states that are not readily inducible in mice with the C57BL/6J background.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18402814     DOI: 10.1016/j.carpath.2007.10.002

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  6 in total

1.  Effects of emotional and physiological stress on plaque instability in apolipoprotein E knockout mice.

Authors:  Tao Zhang; Yongzhi Zhai; Yundai Chen; Zhenhong Zhou; Junjie Yang; Hongbin Liu
Journal:  J Physiol Biochem       Date:  2011-04-22       Impact factor: 4.158

2.  Role of parnaparin in atherosclerosis.

Authors:  Francesca Bonomini; Samanta Taurone; Pierpaolo Parnigotto; Loris Zamai; Luigi F Rodella; Marco Artico; Rita Rezzani
Journal:  Int J Exp Pathol       Date:  2017-02-16       Impact factor: 1.925

3.  Recombinant human erythropoietin suppresses endothelial cell apoptosis and reduces the ratio of Bax to Bcl-2 proteins in the aortas of apolipoprotein E-deficient mice.

Authors:  Jeffrey S Warren; Ying Zhao; Raymond Yung; Anjali Desai
Journal:  J Cardiovasc Pharmacol       Date:  2011-04       Impact factor: 3.105

4.  Zinc deficiency decreased cell viability both in endothelial EA.hy926 cells and mouse aortic culture ex vivo and its implication for anti-atherosclerosis.

Authors:  Young-Eun Cho; Jee-Eun Choi; Md Jahangir Alam; Man-Hyo Lee; Ho-Yong Sohn; John H Beattie; In-Sook Kwun
Journal:  Nutr Res Pract       Date:  2008-06-30       Impact factor: 1.926

5.  The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.

Authors:  Yanmei Zeng; Chenzhong Li; Meiping Guan; Zongji Zheng; Jingjing Li; Wenwei Xu; Ling Wang; Feiying He; Yaoming Xue
Journal:  Cardiovasc Diabetol       Date:  2014-02-04       Impact factor: 9.951

6.  Sitagliptin attenuates high glucose-induced alterations in migration, proliferation, calcification and apoptosis of vascular smooth muscle cells through ERK1/2 signal pathway.

Authors:  Lili Shi; Ye Ji; Dandan Liu; Ying Liu; Ying Xu; Yang Cao; Xiaoyan Jiang; Changqing Xu
Journal:  Oncotarget       Date:  2017-08-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.